TITLE

BTG ANNOUNCES NOVEL INSULIN THERAPY FOR DIABETES

PUB. DATE
November 2002
SOURCE
Worldwide Biotech;Nov2002, Vol. 14 Issue 11, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Provides information on the novel insulin therapy for type diabetes developed by BTG, a global technology commercialization company.
ACCESSION #
7692336

 

Related Articles

  • SYMPOSIUM. Important updates on the management of inpatient hyperglycemia: Practical implications for pharmacists. Moghissi, Etie S. // American Journal of Health-System Pharmacy;8/15/2010, Vol. 67 Issue 16, pS2 

    An introduction to the journal is presented in which the editor discusses the article "Reexamining the Evidence for Inpatient Glucose Control: New Recommendations for Glycemic Targets," "Ensuring Optimal Insulin Utilization in the Hospital Setting: Role of the Pharmacist," by Dr. Janet Kelly,...

  • Toward an ouchless way to take insulin.  // Countdown;Winter96, Vol. 17 Issue 1, p12 

    Reports on attempts to develop a pocket-size device that could both monitor blood sugar and give insulin to diabetics without using a needle. Use of ultrasound to help insulin penetrate the skin without a needle; How the process works; Researchers at the Massachusetts Institute of Technology...

  • Insulin Therapy for Diabetes: Is the Future Now? Hirsch, Irl B. // Clinical Diabetes;Fall2001, Vol. 19 Issue 4, p146 

    Focuses on insulin therapy for diabetes patients in the United States. Use of insulin to minimize risk of hypoglycemia; Problems associated with insulin therapy; Recommendations for the betterment of the study and practice of insulin therapy.

  • Second opinion.  // Mayo Clinic Health Letter;Jul1996, Vol. 14 Issue 7, p8 

    Presents an answer to a query related to the effect of heat on the insulin needs of a diabetic. Changes in diet and activity level; Hypoglycemia.

  • Correction: Efficacy and Safety of Inhaled Insulin Therapy.  // Annals of Internal Medicine;5/16/2006, Vol. 144 Issue 10, p783 

    A correction to an article regarding efficacy and safety of inhaled insulin therapy, published in a previous issue is presented.

  • Correction. Moses, Alan // American Family Physician;12/1/2004, Vol. 70 Issue 11, p2079 

    Presents a correction to the article "Insulin Therapy for Type 2 Diabetes: Rescue, Augmentation, and Replacement of Beta-Cell Function," published in the August 1, 2004 issue of the journal "American Family Physician."

  • Diabetics prefer pre-mixed insulins in pen syringes.  // Modern Medicine;Jan95, Vol. 63 Issue 1, p48 

    Presents an abstract of the article `Premixed Insulin Preparations in Pen Syringes Maintain Glycemic Control and Are Preferred by Patients,' by J.M. Dunbar, T.M. Fiad et al from Diabetes Care dated August 1994.

  • Taking control of diabetes. Abramovitz, Melissa // Current Health 2;Jan1999, Vol. 25 Issue 5, p19 

    Reports on the control of diabetes in the United States. Prevalence of the disease; Types of diabetes; Treatment programs; Therapeutic action of insulin; Efforts to develop drugs to help control diabetes.

  • Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus. Dunn, C.J.; Plosker, G.L.; Dunn, Christopher J; Plosker, Greg L // PharmacoEconomics;2002, Vol. 20 Issue 14, p989 

    Unlabelled: Insulin lispro is a recombinant insulin analogue with transposed amino acids (proline and lysine) at positions 28 and 29 near the C-terminus of the B-chain. The most prominent practical advantage of insulin lispro over human soluble insulin lies in its very rapid onset...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics